Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A US Physician Perspective

American Journal of Kidney Diseases

Volumn 50, Issue 3, 2007, Pages 354-357

  Kasiske, Bertram L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE FACILITY; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PHYSICIAN; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

AMBULATORY CARE FACILITIES; EPOETIN ALFA; HEMATINICS; HUMANS; OWNERSHIP; PHYSICIANS; PRACTICE GUIDELINES; RENAL DIALYSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34548041206     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.07.002     Document Type: Editorial

References (20)

1. Suzuki M., Hirasawa Y., Hirashima K., et al. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO. Contrib Nephrol 76 (1989) 179-192
2. Bahlmann J., Schoter K.H., Scigalla P., et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contrib Nephrol 88 (1991) 90-106
3. Laupacis A. A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian Erythropoietin Study Group. Transplant Proc 23 (1991) 1825-1826
4. Sikole A., Polenakovic M., Spirovska V., Polenakovic B., and Masin G. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 17 (1993) 977-984
5. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
6. Foley R.N., Parfrey P.S., Morgan J., et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58 (2000) 1325-1335
7. Furuland H., Linde T., Ahlmen J., Christensson A., Strombom U., and Danielson B.G. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18 (2003) 353-361
8. Parfrey P.S., Foley R.N., Wittreich B.H., Sullivan D.J., Zagari M.J., and Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 (2005) 2180-2189
9. National Kidney Foundation. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30 suppl 3 (1997) S192-S240
10. Berns J.S., Elzein H., Lynn R.I., Fishbane S., Meisels I.S., and Deoreo P.B. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64 (2003) 1514-1521
11. Lacson Jr. E., Ofsthun N., and Lazarus J.M. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41 (2003) 111-124
12. Thamer M., Zhang Y., Kaufman J., Stefanik K., and Cotter D.J. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States. Am J Kidney Dis 48 (2006) 77-87
13. Collins A.J., Ebben J.P., and Gilbertson D.T. EPO adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis 49 (2007) 135-142
14. United States Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2007), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 191-204
15. Thamer M., Zhang Y., Kaufman J., Cotter D., Dong F., and Hernan M.A. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 (2007) 1667-1674
16. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
17. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
18. Phrommintikul A., Haas S.J., Elsik M., et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369 (2007) 381-388
19. US Food and Drug Administration and Center for Drug Evaluation and Research. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). http://www.fda.gov/cder/drug/infopage/RHE/default.htm. Accessed June 14, 2007
20. Coyne D.W. Use of epoetin in chronic renal failure. JAMA 297 (2007) 1713-1716